|
US3108097A
(en)
*
|
|
1963-10-22 |
|
Ehnojs |
|
US2809194A
(en)
*
|
|
1957-10-08 |
|
Thiadiazine type natriuretic agents |
|
US1286A
(en)
*
|
|
1839-08-13 |
|
Richard else |
|
FR1103113A
(fr)
|
1954-04-15 |
1955-10-31 |
|
Triméthylol-alcanes et leur procédé de préparation
|
|
FR1217929A
(fr)
|
1958-03-03 |
1960-05-06 |
Ciba Geigy |
Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
|
|
BE578515A
(enExample)
*
|
1958-05-07 |
|
|
|
|
DE1302648B
(enExample)
|
1960-09-27 |
|
|
|
|
NL127065C
(enExample)
*
|
1964-04-22 |
|
|
|
|
NL137318C
(enExample)
*
|
1964-06-09 |
|
|
|
|
GB1415295A
(en)
|
1971-10-14 |
1975-11-26 |
Orchimed Sa |
Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
|
|
US3716583A
(en)
*
|
1969-04-16 |
1973-02-13 |
Sumitomo Chemical Co |
Phenoxy carboxylic acid derivative
|
|
US3692895A
(en)
*
|
1970-09-08 |
1972-09-19 |
Norman A Nelson |
Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
|
|
DE2230383C3
(de)
*
|
1971-10-01 |
1981-12-03 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
|
|
US4148923A
(en)
*
|
1972-05-31 |
1979-04-10 |
Synthelabo |
1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
|
|
US3948973A
(en)
*
|
1972-08-29 |
1976-04-06 |
Sterling Drug Inc. |
Halocyclopropyl substituted phenoxyalkanoic acids
|
|
US4626549A
(en)
*
|
1974-01-10 |
1986-12-02 |
Eli Lilly And Company |
Treatment of obesity with aryloxyphenylpropylamines
|
|
US4235896A
(en)
*
|
1975-02-12 |
1980-11-25 |
Orchimed S.A. |
Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
|
|
US4179515A
(en)
*
|
1975-02-12 |
1979-12-18 |
Orchimed S. A. |
Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
|
|
JPS5195049A
(en)
*
|
1975-02-12 |
1976-08-20 |
|
* **********so*****no***tsu*****************************************ni*no
|
|
US4075000A
(en)
*
|
1975-05-27 |
1978-02-21 |
Eli Lilly And Company |
Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
|
|
US4304718A
(en)
*
|
1975-10-06 |
1981-12-08 |
Fujisawa Pharmaceutical Co., Ltd. |
2-Azetidinone compounds and processes for preparation thereof
|
|
US4576753A
(en)
*
|
1975-10-06 |
1986-03-18 |
Fujisawa Pharmaceutical Co., Ltd. |
Azetidinone compounds and processes for preparation thereof
|
|
US4472309A
(en)
*
|
1975-10-06 |
1984-09-18 |
Fujisawa Pharmaceutical Co., Ltd. |
2-Azetidinone compounds and processes for preparation thereof
|
|
US4166907A
(en)
*
|
1976-11-01 |
1979-09-04 |
E. R. Squibb & Sons, Inc. |
3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
|
|
US4144232A
(en)
*
|
1976-12-23 |
1979-03-13 |
Eli Lilly And Company |
Substituted azetidin-2-one antibiotics
|
|
FR2403078A1
(fr)
*
|
1977-09-19 |
1979-04-13 |
Lafon Labor |
Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
|
|
IT1157365B
(it)
*
|
1977-10-24 |
1987-02-11 |
Sandoz Ag |
Medicamenti per trattare l'obesita' o ridurre il peso del corpo
|
|
FR2408577A1
(fr)
|
1977-11-14 |
1979-06-08 |
Devinter Sa |
Nouveau procede de synthese d'esters para chlorobenzoyl phenoxy isobutyriques
|
|
NZ191762A
(en)
|
1978-10-19 |
1982-09-14 |
Merck & Co Inc |
Hypocholesteremic composition containing cholesterol synthesis inhibitor and anion exchange resin
|
|
US4250191A
(en)
*
|
1978-11-30 |
1981-02-10 |
Edwards K David |
Preventing renal failure
|
|
US4375475A
(en)
*
|
1979-08-17 |
1983-03-01 |
Merck & Co., Inc. |
Substituted pyranone inhibitors of cholesterol synthesis
|
|
US4260743A
(en)
*
|
1979-12-31 |
1981-04-07 |
Gist-Brocades N.V. |
Preparation of β-lactams and intermediates therefor
|
|
US4444784A
(en)
*
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
|
ES8101585A1
(es)
|
1980-02-15 |
1980-12-16 |
Especialidades Farmaco Terape |
Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
|
|
FR2494112B1
(enExample)
|
1980-11-19 |
1986-01-10 |
Laruelle Claude |
|
|
DE3107100A1
(de)
*
|
1981-02-20 |
1982-09-09 |
Schering Ag, 1000 Berlin Und 4619 Bergkamen |
Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
|
|
US4500456A
(en)
*
|
1981-03-09 |
1985-02-19 |
Eli Lilly And Company |
Preparation of 4-fluoroazetidinones using FClO3
|
|
US4784734A
(en)
*
|
1981-04-10 |
1988-11-15 |
Otsuka Kagaku Yakuhin Kabushiki Kaisha |
Azetidinone derivatives and process for the preparation of the same
|
|
US4602005A
(en)
*
|
1982-05-17 |
1986-07-22 |
Medical Research Foundation Of Oregon |
Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
|
|
US4602003A
(en)
*
|
1982-05-17 |
1986-07-22 |
Medical Research Foundation Of Oregon |
Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
|
|
US4534786A
(en)
*
|
1982-06-23 |
1985-08-13 |
Chevron Research Company |
1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
|
|
US4443372A
(en)
*
|
1982-06-23 |
1984-04-17 |
Chevron Research Company |
1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
|
|
US4595532A
(en)
*
|
1983-02-02 |
1986-06-17 |
University Of Notre Dame Du Lac |
N-(substituted-methyl)-azetidin-2-ones
|
|
CA1256650A
(en)
*
|
1983-03-25 |
1989-06-27 |
Toshinari Tamura |
Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
|
|
DE3484362D1
(de)
*
|
1983-03-28 |
1991-05-08 |
Ciba Geigy Ag |
Verfahren zur herstellung von optisch aktiven azetidinonen.
|
|
US4675399A
(en)
*
|
1983-03-28 |
1987-06-23 |
Notre Dame University |
Cyclization process for β-lactams
|
|
WO1985004876A1
(fr)
*
|
1984-04-24 |
1985-11-07 |
Takeda Chemical Industries, Ltd. |
Derives de 2-azetidinone et leur procede de preparation
|
|
US4576749A
(en)
*
|
1983-10-03 |
1986-03-18 |
E. R. Squibb & Sons, Inc. |
3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
|
|
US5229510A
(en)
*
|
1983-12-01 |
1993-07-20 |
Merck & Co., Inc. |
β-lactams useful in determining the amount of elastase in a clinical sample
|
|
US5229381A
(en)
*
|
1983-12-01 |
1993-07-20 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US4680391A
(en)
|
1983-12-01 |
1987-07-14 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US4654362A
(en)
*
|
1983-12-05 |
1987-03-31 |
Janssen Pharmaceutica, N.V. |
Derivatives of 2,2'-iminobisethanol
|
|
FR2561916B1
(fr)
*
|
1984-03-30 |
1987-12-11 |
Lafon Labor |
Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
|
|
US4581170A
(en)
*
|
1984-08-03 |
1986-04-08 |
E. R. Squibb & Sons, Inc. |
N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
|
|
US4633017A
(en)
*
|
1984-08-03 |
1986-12-30 |
E. R. Squibb & Sons, Inc. |
N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
|
|
US4576748A
(en)
*
|
1984-09-17 |
1986-03-18 |
Merck & Co., Inc. |
3-Hydroxy-3-aminoethyl β-lactams
|
|
US4647576A
(en)
|
1984-09-24 |
1987-03-03 |
Warner-Lambert Company |
Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
|
|
US4620867A
(en)
*
|
1984-09-28 |
1986-11-04 |
Chevron Research Company |
1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
|
|
AR240698A1
(es)
*
|
1985-01-19 |
1990-09-28 |
Takeda Chemical Industries Ltd |
Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
|
|
US4642903A
(en)
*
|
1985-03-26 |
1987-02-17 |
R. P. Scherer Corporation |
Freeze-dried foam dosage form
|
|
US4680289A
(en)
*
|
1985-06-05 |
1987-07-14 |
Progenics, Inc. |
Treatment of obesity and diabetes using sapogenins
|
|
JPH0679559B2
(ja)
|
1985-06-06 |
1994-10-12 |
三共株式会社 |
光学活性アゼチジノン誘導体の製法
|
|
JPH01501470A
(ja)
|
1986-01-23 |
1989-05-25 |
ジ・アップジョン・カンパニ− |
抗菌性ｎ−アシル−２−アゼチジノン
|
|
EP0234484B1
(en)
*
|
1986-02-19 |
1993-10-20 |
Sanraku Incorporated |
Novel azetidinone derivatives
|
|
GB8607312D0
(en)
*
|
1986-03-25 |
1986-04-30 |
Ici Plc |
Therapeutic agents
|
|
WO1987005804A1
(en)
|
1986-04-01 |
1987-10-08 |
The Upjohn Company |
Methylprednisolone/sodium carboxymethyl starch tablet composition
|
|
FR2598146B1
(fr)
*
|
1986-04-30 |
1989-01-20 |
Rech Ind |
Nouveau procede de preparation de fibrates.
|
|
DE3621861A1
(de)
*
|
1986-06-30 |
1988-01-14 |
Laszlo Dr Med Ilg |
Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
|
|
JPS6317859A
(ja)
|
1986-07-11 |
1988-01-25 |
Sagami Chem Res Center |
フルオロアゼチジノン誘導体
|
|
FR2602423B1
(fr)
*
|
1986-08-08 |
1989-05-05 |
Ethypharm Sa |
Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
|
|
US4814354A
(en)
*
|
1986-09-26 |
1989-03-21 |
Warner-Lambert Company |
Lipid regulating agents
|
|
ZA877398B
(en)
|
1986-10-03 |
1989-05-30 |
Lilly Co Eli |
7-((meta-substituted)phenylglycine)1-carba-1-dethiacephalosporins
|
|
US4803266A
(en)
*
|
1986-10-17 |
1989-02-07 |
Taisho Pharmaceutical Co., Ltd. |
3-Oxoalkylidene-2-azetidinone derivatives
|
|
ES2052584T3
(es)
|
1986-12-15 |
1994-07-16 |
Lilly Co Eli |
El complejo antibiotico a10255 y factores, proceso, microorganismos para su produccion.
|
|
US5229362A
(en)
*
|
1986-12-15 |
1993-07-20 |
Eli Lilly And Company |
Antibiotic A10255 complex and factors, and process and production therefor
|
|
PH25145A
(en)
*
|
1986-12-15 |
1991-02-19 |
Laverne Dwaine Boeck |
Process for producing the a10255 complex and corresponding microorganism
|
|
JPS63156788A
(ja)
|
1986-12-22 |
1988-06-29 |
Sanraku Inc |
光学活性アゼチジノン類
|
|
AU1422388A
(en)
|
1987-01-27 |
1988-08-10 |
Warner-Lambert Company |
Lipid regulating compositions
|
|
US5110730A
(en)
*
|
1987-03-31 |
1992-05-05 |
The Scripps Research Institute |
Human tissue factor related DNA segments
|
|
EP0288973B1
(en)
|
1987-04-28 |
1993-01-13 |
Fujisawa Astra Ltd. |
Benzothiazolinone derivatives, their production and pharmaceutical composition
|
|
GB8710965D0
(en)
|
1987-05-08 |
1987-06-10 |
Smith Kline French Lab |
Pharmaceutical compositions
|
|
US5106833A
(en)
*
|
1987-07-23 |
1992-04-21 |
Washington University |
Coagulation inhibitors
|
|
MY104063A
(en)
|
1987-10-06 |
1993-11-30 |
Lilly Co Eli |
Crystalline (beta)-lactam hydrate
|
|
US5091525A
(en)
*
|
1987-10-07 |
1992-02-25 |
Eli Lilly And Company |
Monohydrate and DMF solvates of a new carbacephem antibiotic
|
|
US4834846A
(en)
*
|
1987-12-07 |
1989-05-30 |
Merck & Co., Inc. |
Process for deblocking N-substituted β-lactams
|
|
US5385885A
(en)
|
1988-01-15 |
1995-01-31 |
Gasic; Gregory P. |
Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
|
|
FR2627696B1
(fr)
*
|
1988-02-26 |
1991-09-13 |
Fournier Innovation Synergie |
Nouvelle forme galenique du fenofibrate
|
|
DE3807895A1
(de)
*
|
1988-03-10 |
1989-09-21 |
Knoll Ag |
Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
|
|
EP0333268A1
(en)
|
1988-03-18 |
1989-09-20 |
Merck & Co. Inc. |
Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
|
|
NZ228600A
(en)
|
1988-04-11 |
1992-02-25 |
Merck & Co Inc |
1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
|
|
GB8813012D0
(en)
*
|
1988-06-02 |
1988-07-06 |
Norsk Hydro As |
Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
|
|
FR2634376B1
(fr)
|
1988-07-21 |
1992-04-17 |
Farmalyoc |
Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
|
|
US4952689A
(en)
*
|
1988-10-20 |
1990-08-28 |
Taisho Pharmaceutical Co., Ltd. |
3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
|
|
CA2002596A1
(en)
|
1988-11-14 |
1990-05-14 |
Thomas M. Eckrich |
Hydrates of b-lactam antibiotic
|
|
CA1340977C
(en)
|
1988-11-15 |
2000-04-25 |
Monty Krieger |
Scavenger receptor protein and antibody thereto
|
|
US5073374A
(en)
*
|
1988-11-30 |
1991-12-17 |
Schering Corporation |
Fast dissolving buccal tablet
|
|
US5112616A
(en)
*
|
1988-11-30 |
1992-05-12 |
Schering Corporation |
Fast dissolving buccal tablet
|
|
US4876365A
(en)
*
|
1988-12-05 |
1989-10-24 |
Schering Corporation |
Intermediate compounds for preparing penems and carbapenems
|
|
US5260305A
(en)
*
|
1988-12-12 |
1993-11-09 |
E. R. Squibb & Sons, Inc. |
Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
|
|
FR2640621B1
(fr)
|
1988-12-19 |
1992-10-30 |
Centre Nat Rech Scient |
N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
|
|
US4990535A
(en)
*
|
1989-05-03 |
1991-02-05 |
Schering Corporation |
Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
|
|
CA2016467A1
(en)
|
1989-06-05 |
1990-12-05 |
Martin Eisman |
Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
|
|
JPH03108490A
(ja)
*
|
1989-06-30 |
1991-05-08 |
Shionogi & Co Ltd |
フォスフォリパーゼａ↓２阻害物質
|
|
US5021461A
(en)
*
|
1989-07-26 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Method of treating diabetes mellitus with bisphenol derivatives
|
|
US4983597A
(en)
|
1989-08-31 |
1991-01-08 |
Merck & Co., Inc. |
Beta-lactams as anticholesterolemic agents
|
|
IL95574A
(en)
|
1989-09-09 |
1994-11-11 |
Knoll Ag |
Colestyramine preparation
|
|
US5219574A
(en)
*
|
1989-09-15 |
1993-06-15 |
Cima Labs. Inc. |
Magnesium carbonate and oil tableting aid and flavoring additive
|
|
US5178878A
(en)
*
|
1989-10-02 |
1993-01-12 |
Cima Labs, Inc. |
Effervescent dosage form with microparticles
|
|
US5223264A
(en)
*
|
1989-10-02 |
1993-06-29 |
Cima Labs, Inc. |
Pediatric effervescent dosage form
|
|
US5188825A
(en)
*
|
1989-12-28 |
1993-02-23 |
Iles Martin C |
Freeze-dried dosage forms and methods for preparing the same
|
|
CA2039763A1
(en)
|
1990-04-30 |
1991-10-31 |
Henry Y. Pan |
Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
|
|
CA2040865C
(en)
|
1990-05-15 |
2002-07-23 |
James L. Bergey |
Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
|
|
US5298497A
(en)
|
1990-05-15 |
1994-03-29 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of hypertension employing a cholesterol lowering drug
|
|
US5622985A
(en)
|
1990-06-11 |
1997-04-22 |
Bristol-Myers Squibb Company |
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
|
|
CA2042526A1
(en)
|
1990-06-11 |
1991-12-12 |
Adeoye Y. Olukotun |
Method for preventing a second heart attack employing an hmg coa reductase inhibitor
|
|
US5120729A
(en)
|
1990-06-20 |
1992-06-09 |
Merck & Co., Inc. |
Beta-lactams as antihypercholesterolemics
|
|
ZA915372B
(en)
*
|
1990-07-17 |
1993-03-31 |
Lilly Co Eli |
Pyrazolidinone cck and gastrin antagonists and pharmaceutical formulations thereof
|
|
CA2048395A1
(en)
|
1990-08-23 |
1992-02-24 |
Henry Y. Pan |
Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
|
|
US5120713A
(en)
*
|
1990-09-10 |
1992-06-09 |
Applied Research Systems Ars Holding N.V. |
Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
|
|
US5075313A
(en)
|
1990-09-13 |
1991-12-24 |
Eli Lilly And Company |
3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
|
|
IL99658A0
(en)
|
1990-10-15 |
1992-08-18 |
Merck & Co Inc |
Substituted azetidinones and pharmaceutical compositions containing them
|
|
US5190970A
(en)
*
|
1990-10-19 |
1993-03-02 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
|
|
US5130333A
(en)
*
|
1990-10-19 |
1992-07-14 |
E. R. Squibb & Sons, Inc. |
Method for treating type II diabetes employing a cholesterol lowering drug
|
|
CA2052014A1
(en)
|
1990-10-19 |
1992-04-20 |
Henry Y. Pan |
Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
|
|
JP2640986B2
(ja)
*
|
1990-11-08 |
1997-08-13 |
高砂香料工業株式会社 |
（１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
|
|
IL100091A
(en)
|
1990-12-12 |
1998-08-16 |
Zeneca Ltd |
Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
|
|
US5552160A
(en)
|
1991-01-25 |
1996-09-03 |
Nanosystems L.L.C. |
Surface modified NSAID nanoparticles
|
|
US5145684A
(en)
*
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
AU642066B2
(en)
|
1991-01-25 |
1993-10-07 |
Nanosystems L.L.C. |
X-ray contrast compositions useful in medical imaging
|
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
|
IT1244699B
(it)
|
1991-02-01 |
1994-08-08 |
Luso Farmaco Inst |
Processo per la preparazione di acidi 3 acilammino-4- carbamoilossimetil-2-azetidinone-l-solfonici ed intermedi per la loro preparazione
|
|
US5157025A
(en)
*
|
1991-04-01 |
1992-10-20 |
E. R. Squibb & Sons, Inc. |
Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
|
|
US5348953A
(en)
|
1991-06-25 |
1994-09-20 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US5464632C1
(en)
|
1991-07-22 |
2001-02-20 |
Prographarm Lab |
Rapidly disintegratable multiparticular tablet
|
|
US5561227A
(en)
|
1991-07-23 |
1996-10-01 |
Schering Corporation |
Process for the stereospecific synthesis of azetidinones
|
|
TW223059B
(enExample)
|
1991-07-23 |
1994-05-01 |
Schering Corp |
|
|
US5688787A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
|
|
US5688785A
(en)
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
JP2620437B2
(ja)
|
1991-09-27 |
1997-06-11 |
宇部興産株式会社 |
ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
|
|
WO1993007167A1
(en)
|
1991-10-04 |
1993-04-15 |
The Procter & Gamble Company |
Cholesterol lowering compounds and process for making them
|
|
US5162117A
(en)
*
|
1991-11-22 |
1992-11-10 |
Schering Corporation |
Controlled release flutamide composition
|
|
AU659506B2
(en)
|
1991-11-25 |
1995-05-18 |
Pfizer Inc. |
Method for making steroidal peracyl glycosides
|
|
DE4203932A1
(de)
|
1992-02-11 |
1993-08-12 |
Deutsche Aerospace |
Sende-/empfangsmodul
|
|
US6063764A
(en)
|
1992-06-01 |
2000-05-16 |
Washington University & Chiron Corp. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
|
CA2139104A1
(en)
|
1992-06-26 |
1994-01-06 |
Michael P. Deninno |
Steroidal glycosides for treating hypercholesterolemia
|
|
US5278176A
(en)
*
|
1992-08-21 |
1994-01-11 |
Abbott Laboratories |
Nicotine derivatives that enhance cognitive function
|
|
WO1994010143A1
(en)
|
1992-10-27 |
1994-05-11 |
Merck & Co., Inc. |
New substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US5631363A
(en)
|
1992-11-13 |
1997-05-20 |
Tanabe Seiyaku Co., Ltd. |
Azetidinone compound and process for preparation thereof
|
|
AU660852B2
(en)
|
1992-11-25 |
1995-07-06 |
Elan Pharma International Limited |
Method of grinding pharmaceutical substances
|
|
WO1994020535A1
(en)
|
1992-12-11 |
1994-09-15 |
Corvas International, Inc. |
ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
|
|
US5429824A
(en)
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
|
US5358852A
(en)
|
1992-12-21 |
1994-10-25 |
Eastman Kodak Company |
Use of calcium in immunoassay for measurement of C-reactive protein
|
|
LT3300B
(en)
|
1992-12-23 |
1995-06-26 |
Schering Corp |
Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
|
|
LT3595B
(en)
|
1993-01-21 |
1995-12-27 |
Schering Corp |
Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
|
|
US5563264A
(en)
|
1993-02-10 |
1996-10-08 |
Shionogi & Co., Ltd. |
Preparation of βlactam compounds
|
|
US5503846A
(en)
|
1993-03-17 |
1996-04-02 |
Cima Labs, Inc. |
Base coated acid particles and effervescent formulation incorporating same
|
|
US5412092A
(en)
|
1993-04-23 |
1995-05-02 |
Bristol-Myers Squibb Company |
N-substituted 2-azetidinones
|
|
IL109568A0
(en)
|
1993-05-19 |
1994-08-26 |
Fujisawa Pharmaceutical Co |
Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
|
|
US5703188A
(en)
|
1993-06-02 |
1997-12-30 |
Geltex Pharmaceuticals, Inc. |
Process for removing bile salts from a patient and compositions therefor
|
|
US5550229A
(en)
|
1993-06-23 |
1996-08-27 |
Tanabe Seiyaku Co., Ltd. |
Alkylation process for preparing azetidinone compound and starting compound therefor
|
|
DE69428280T2
(de)
|
1993-07-09 |
2002-06-13 |
Schering Corp., Kenilworth |
Verfahren zur herstellung von azetidinonen
|
|
EP0804170B1
(en)
|
1993-07-09 |
2001-11-14 |
R.P. Scherer Corporation |
Method for making freeze dried drug dosage forms
|
|
AU7376494A
(en)
|
1993-08-04 |
1995-02-28 |
Andrulis Pharmaceuticals Corporation |
Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
|
|
AU7397094A
(en)
|
1993-08-30 |
1995-03-22 |
Merck & Co., Inc. |
Prevention and treatment of alzheimer's disease
|
|
US5622719A
(en)
|
1993-09-10 |
1997-04-22 |
Fuisz Technologies Ltd. |
Process and apparatus for making rapidly dissolving dosage units and product therefrom
|
|
US5851553A
(en)
|
1993-09-10 |
1998-12-22 |
Fuisz Technologies, Ltd. |
Process and apparatus for making rapidly dissolving dosage units and product therefrom
|
|
US5895664A
(en)
|
1993-09-10 |
1999-04-20 |
Fuisz Technologies Ltd. |
Process for forming quickly dispersing comestible unit and product therefrom
|
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5976570A
(en)
|
1993-12-21 |
1999-11-02 |
Applied Analytical Industries, Inc. |
Method for preparing low dose pharmaceutical products
|
|
WO1995018143A1
(en)
|
1993-12-28 |
1995-07-06 |
Pfizer Inc. |
Hypocholesterolemic agents
|
|
US6369103B1
(en)
|
1994-01-18 |
2002-04-09 |
Bristol-Myers Squibb Company |
Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
|
|
US5595761A
(en)
|
1994-01-27 |
1997-01-21 |
The Board Of Regents Of The University Of Oklahoma |
Particulate support matrix for making a rapidly dissolving tablet
|
|
US5576014A
(en)
|
1994-01-31 |
1996-11-19 |
Yamanouchi Pharmaceutical Co., Ltd |
Intrabuccally dissolving compressed moldings and production process thereof
|
|
GB9401892D0
(en)
|
1994-02-01 |
1994-03-30 |
Boots Co Plc |
Therapeutic agents
|
|
US5635210A
(en)
|
1994-02-03 |
1997-06-03 |
The Board Of Regents Of The University Of Oklahoma |
Method of making a rapidly dissolving tablet
|
|
US5627176A
(en)
*
|
1994-03-25 |
1997-05-06 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
GB9406074D0
(en)
|
1994-03-26 |
1994-05-18 |
Glaxo Spa |
Chemical process
|
|
DE4414538A1
(de)
|
1994-04-26 |
1995-11-02 |
Klinge Co Chem Pharm Fab |
Präparate zur Therapie der kombinierten Hyperlipidämie mit einem Gehalt an einem p-Oxybenzoesäurederivat und einem Fibrat
|
|
US5554746A
(en)
|
1994-05-16 |
1996-09-10 |
Isis Pharmaceuticals, Inc. |
Lactam nucleic acids
|
|
TW384224B
(en)
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
|
US5718388A
(en)
|
1994-05-25 |
1998-02-17 |
Eastman Kodak |
Continuous method of grinding pharmaceutical substances
|
|
US5567439A
(en)
|
1994-06-14 |
1996-10-22 |
Fuisz Technologies Ltd. |
Delivery of controlled-release systems(s)
|
|
WO1995035277A1
(en)
*
|
1994-06-20 |
1995-12-28 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US6429289B1
(en)
|
1994-06-23 |
2002-08-06 |
Massachusetts Institute Of Technology |
Class BI and CI scavenger receptors
|
|
EP0782451A1
(en)
|
1994-09-20 |
1997-07-09 |
Pfizer Inc. |
Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
|
|
GB9421836D0
(en)
|
1994-10-28 |
1994-12-14 |
Scherer Corp R P |
Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
|
|
GB9421816D0
(en)
|
1994-10-29 |
1994-12-14 |
Smithkline Beecham Plc |
Novel compounds
|
|
US5624920A
(en)
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
|
BR9510420A
(pt)
|
1994-12-22 |
2004-04-20 |
Smithkline Beecham Plc |
Azetidin-2-onas substituìdas para o tratamento de aterosclerose
|
|
US5902726A
(en)
|
1994-12-23 |
1999-05-11 |
Glaxo Wellcome Inc. |
Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
|
|
ATE214924T1
(de)
|
1994-12-28 |
2002-04-15 |
Janssen Pharmaceutica Nv |
Verwendung von nebivolol als anti-atherogenisches mittel
|
|
US5545628A
(en)
|
1995-01-10 |
1996-08-13 |
Galephar P.R. Inc. |
Pharmaceutical composition containing fenofibrate
|
|
FR2730231B1
(fr)
|
1995-02-02 |
1997-04-04 |
Fournier Sca Lab |
Association de fenofibrate et de vitamine e, utilisation en therapeutique
|
|
US5639475A
(en)
|
1995-02-03 |
1997-06-17 |
Eurand America, Incorporated |
Effervescent microcapsules
|
|
US5518738A
(en)
|
1995-02-09 |
1996-05-21 |
Nanosystem L.L.C. |
Nanoparticulate nsaid compositions
|
|
US5591456A
(en)
|
1995-02-10 |
1997-01-07 |
Nanosystems L.L.C. |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
|
|
US5510118A
(en)
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
|
US5747001A
(en)
|
1995-02-24 |
1998-05-05 |
Nanosystems, L.L.C. |
Aerosols containing beclomethazone nanoparticle dispersions
|
|
US5998441A
(en)
|
1995-02-28 |
1999-12-07 |
Eli Lilly And Company |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
US5639739A
(en)
|
1995-03-24 |
1997-06-17 |
The Dupont Merck Pharmaceutical Company |
Imidazole containing aminoboronic acids
|
|
US5759865A
(en)
|
1995-05-03 |
1998-06-02 |
Eli Lilly And Company |
Combinatorial process for synthesizing azetidinone analogs
|
|
DE19518988A1
(de)
|
1995-05-29 |
1996-12-05 |
Basf Ag |
Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
|
|
JP3144624B2
(ja)
*
|
1995-06-02 |
2001-03-12 |
杏林製薬株式会社 |
Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
|
|
US5612378A
(en)
|
1995-06-06 |
1997-03-18 |
3-Dimensional Pharmaceuticals, Inc. |
Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
|
|
US5607697A
(en)
|
1995-06-07 |
1997-03-04 |
Cima Labs, Incorporated |
Taste masking microparticles for oral dosage forms
|
|
US5612353A
(en)
|
1995-06-07 |
1997-03-18 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
|
|
AU6039296A
(en)
|
1995-06-07 |
1996-12-30 |
G.D. Searle & Co. |
Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
|
|
IL118778A
(en)
|
1995-07-03 |
1999-07-14 |
Sankyo Co |
Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
|
|
FR2737121B1
(fr)
|
1995-07-27 |
1997-10-03 |
Cl Pharma |
Nouvelles formulations galeniques du fenofibrate et leurs applications
|
|
US5698527A
(en)
|
1995-08-08 |
1997-12-16 |
Merck & Co., Inc. |
Steroidal glycosides as antihyperlipidemic agents
|
|
FR2738817B1
(fr)
|
1995-09-14 |
1997-10-17 |
Adir |
Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US5618707A
(en)
|
1996-01-04 |
1997-04-08 |
Schering Corporation |
Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
|
|
US5808056A
(en)
|
1995-10-31 |
1998-09-15 |
Merck & Co., Inc. |
Process for preparing substituted azetidinones
|
|
SK283552B6
(sk)
|
1995-10-31 |
2003-09-11 |
Schering Corporation |
2-Azetidinóny substituované cukrovými zvyškami, farmaceutický prípravok, kombinovaný farmaceutický prípravok a ich použitie
|
|
WO1997016424A1
(en)
|
1995-11-02 |
1997-05-09 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
|
BR9611306A
(pt)
|
1995-11-14 |
1999-12-28 |
Knoll Pharmaceuticals Co |
Preparação farmacêutica e, composto farmacêutica estável.
|
|
US5925333A
(en)
|
1995-11-15 |
1999-07-20 |
Massachusetts Institute Of Technology |
Methods for modulation of lipid uptake
|
|
JPH09143156A
(ja)
|
1995-11-17 |
1997-06-03 |
Tanabe Seiyaku Co Ltd |
アセトキシアゼチジノン誘導体の製法及びその合成中間体
|
|
US5807577A
(en)
|
1995-11-22 |
1998-09-15 |
Lab Pharmaceutical Research International Inc. |
Fast-melt tablet and method of making same
|
|
US5807578A
(en)
|
1995-11-22 |
1998-09-15 |
Lab Pharmaceutical Research International Inc. |
Fast-melt tablet and method of making same
|
|
JP2000505063A
(ja)
|
1995-12-08 |
2000-04-25 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
アテローム性動脈硬化症の治療のためのアゼチジノン化合物
|
|
US6080767A
(en)
|
1996-01-02 |
2000-06-27 |
Aventis Pharmaceuticals Products Inc. |
Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
|
|
GB9600464D0
(en)
*
|
1996-01-09 |
1996-03-13 |
Smithkline Beecham Plc |
Novel method
|
|
US5847008A
(en)
|
1996-02-02 |
1998-12-08 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
|
WO1997028149A1
(en)
|
1996-02-02 |
1997-08-07 |
Merck & Co., Inc. |
Method for raising hdl cholesterol levels
|
|
US5859051A
(en)
|
1996-02-02 |
1999-01-12 |
Merck & Co., Inc. |
Antidiabetic agents
|
|
GB9604242D0
(en)
|
1996-02-28 |
1996-05-01 |
Glaxo Wellcome Inc |
Chemical compounds
|
|
DE19608750A1
(de)
|
1996-03-06 |
1997-09-11 |
Durachemie Gmbh & Co Kg |
Verfahren zur Herstellung von Fenofibrat-Präparaten
|
|
IL117702A0
(en)
|
1996-03-28 |
1996-07-23 |
Tel Aviv Medical Center Resear |
Drug for hyperlipoproteinemia
|
|
GB9606805D0
(en)
|
1996-03-30 |
1996-06-05 |
Glaxo Wellcome Inc |
Medicaments
|
|
US5858409A
(en)
|
1996-04-17 |
1999-01-12 |
Fmc Corporation |
Hydrolyzed cellulose granulations for pharmaceuticals
|
|
EP0904082A4
(en)
*
|
1996-04-17 |
2001-09-26 |
Merck & Co Inc |
COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
|
|
IL126696A0
(en)
|
1996-04-26 |
1999-08-17 |
Smithkline Beecham Plc |
Azetidinone derivatives for the treatment of atherosclerosis
|
|
US5843984A
(en)
|
1996-05-09 |
1998-12-01 |
Eli Lilly And Company |
Sulfated benzothiophene derivatives, methods of use and formulations containing same
|
|
JP3366648B2
(ja)
*
|
1996-05-24 |
2003-01-14 |
シェーリング コーポレイション |
増大したバイオアベイラビリティーを有する抗真菌組成物
|
|
US5886171A
(en)
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
|
US5739321A
(en)
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
|
US6245743B1
(en)
|
1996-06-05 |
2001-06-12 |
Cor Therapeutics, Inc. |
Inhibitors of factor Xa
|
|
GB9611947D0
(en)
|
1996-06-07 |
1996-08-07 |
Glaxo Group Ltd |
Medicaments
|
|
JP3938942B2
(ja)
|
1996-06-12 |
2007-06-27 |
協和醗酵工業株式会社 |
脂質代謝改善剤
|
|
US5965553A
(en)
|
1996-06-20 |
1999-10-12 |
Pfizer Inc. |
Squalene synthetase inhibitors
|
|
WO1998001119A2
(en)
|
1996-07-09 |
1998-01-15 |
Merck & Co., Inc. |
Pharmaceutical compositions comprising simvastatin
|
|
US6139873A
(en)
|
1996-07-10 |
2000-10-31 |
Cedars-Sinai Medical Center |
Combined pharmaceutical estrogen-androgen-progestin
|
|
US5883109A
(en)
|
1996-07-24 |
1999-03-16 |
Bristol-Myers Squibb Company |
Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
|
|
US5952003A
(en)
|
1996-08-01 |
1999-09-14 |
Novartis Corporation |
Terazosin capsules
|
|
WO1998005331A2
(en)
|
1996-08-02 |
1998-02-12 |
Ligand Pharmaceuticals Incorporated |
Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
|
|
US6057342A
(en)
|
1996-08-16 |
2000-05-02 |
Dupont Pharmaceutical Co. |
Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
|
|
US6251852B1
(en)
|
1996-09-18 |
2001-06-26 |
Merck & Co., Inc. |
Combination therapy for reducing the risks associated with cardiovascular disease
|
|
US6235706B1
(en)
|
1996-09-18 |
2001-05-22 |
Merck & Co., Inc. |
Combination therapy for reducing the risks associated with cardiovascular disease
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
WO1998012176A1
(en)
|
1996-09-23 |
1998-03-26 |
Synphar Laboratories Inc. |
3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
|
|
KR100353304B1
(ko)
|
1996-10-01 |
2002-09-30 |
에스알아이 인터내셔널 |
맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
|
|
US6262047B1
(en)
|
1996-10-11 |
2001-07-17 |
Cor Therapeutics, Inc. |
Selective factor Xa inhibitors
|
|
US5756470A
(en)
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
KR100512671B1
(ko)
|
1996-11-27 |
2005-09-07 |
아벤티스 파마슈티칼스 인크. |
항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물
|
|
US6090839A
(en)
|
1996-12-23 |
2000-07-18 |
Merck & Co., Inc. |
Antidiabetic agents
|
|
FR2758459B1
(fr)
|
1997-01-17 |
1999-05-07 |
Pharma Pass |
Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
|
|
US6066653A
(en)
|
1997-01-17 |
2000-05-23 |
Bristol-Myers Squibb Co. |
Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
|
|
CA2276467A1
(en)
|
1997-01-17 |
1998-07-23 |
Bristol-Myers Squibb Company |
Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
|
|
FR2758461A1
(fr)
|
1997-01-17 |
1998-07-24 |
Pharma Pass |
Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
|
|
DK1625852T3
(da)
*
|
1997-02-28 |
2010-09-20 |
Sanofi Pasteur Biologics Co |
Kimæriske flavivirusvacciner
|
|
AU6773598A
(en)
|
1997-03-26 |
1998-10-20 |
Institut Pasteur |
Treatment of gastrointestinal disease with ppar modulators
|
|
FR2761266B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
|
|
AU7100898A
(en)
|
1997-04-02 |
1998-10-22 |
Brigham And Women's Hospital |
Means of ascertaining an individual's risk profile for atherosclerotic disease
|
|
US6024981A
(en)
|
1997-04-16 |
2000-02-15 |
Cima Labs Inc. |
Rapidly dissolving robust dosage form
|
|
DE19716120A1
(de)
|
1997-04-17 |
1998-10-22 |
Europ Lab Molekularbiolog |
Verwendung von cholesterinsenkenden Mitteln
|
|
US6162805A
(en)
|
1997-04-24 |
2000-12-19 |
Merck Sharp & Dohme Limited |
Use of an NK-1 receptor antagonist and an SSRI for treating obesity
|
|
ES2125198B1
(es)
*
|
1997-05-13 |
1999-11-16 |
Vita Invest Sa |
Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
|
|
PL194329B1
(pl)
|
1997-05-14 |
2007-05-31 |
Atherogenics Inc |
Zastosowanie monoestru probukolu kwasu bursztynowego lub jego farmaceutycznie dopuszczalnej soli dowytwarzania leku do leczenia choroby, której mediatorem jest VCAM-1
|
|
US6423754B1
(en)
|
1997-06-18 |
2002-07-23 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with polyallylamine polymers
|
|
AU8355998A
(en)
|
1997-07-24 |
1999-02-16 |
Yamanouchi Pharmaceutical Co., Ltd. |
Medicinal compositions with cholesterol-lowering effect
|
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
|
DK1017390T3
(da)
|
1997-07-31 |
2007-06-11 |
Kos Life Sciences Inc |
Coated tablet, der omfatter nikotinsyre eller en forbindelse, der metaboliseres til nikotinsyre, i en form med langvarig frigivelse og en HMG-CoA-reduktaseinhibitor i en form med öjeblikkelig frigivelse
|
|
US6117429A
(en)
|
1997-08-11 |
2000-09-12 |
Weider Nutrition International, Inc |
Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
|
|
US5886191A
(en)
|
1997-08-18 |
1999-03-23 |
Dupont Pharmaceuticals Company |
Amidinoindoles, amidinoazoles, and analogs thereof
|
|
US5869098A
(en)
|
1997-08-20 |
1999-02-09 |
Fuisz Technologies Ltd. |
Fast-dissolving comestible units formed under high-speed/high-pressure conditions
|
|
AR016827A1
(es)
*
|
1997-08-22 |
2001-08-01 |
Smithkline Beecham Corp |
PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
|
|
US6180660B1
(en)
|
1997-08-26 |
2001-01-30 |
Merck & Co., Inc. |
Cholesterol-lowering therapy
|
|
CA2300165A1
(en)
|
1997-08-26 |
1999-03-04 |
Merck & Co., Inc. |
Cholesterol-lowering therapy
|
|
US6143885A
(en)
|
1997-08-27 |
2000-11-07 |
Merck & Co., Inc. |
Preparation of beta-methyl carbapenem intermediates
|
|
GT199800126A
(es)
|
1997-08-29 |
2000-01-29 |
|
Terapia de combinacion.
|
|
ES2216309T3
(es)
|
1997-09-09 |
2004-10-16 |
Bristol-Myers Squibb Pharma Company |
Bencimidazolinonas, benzoxazolinonas, benzopiperazinonas, indanonas y sus derivados como inhibidores del factor xa.
|
|
AU8996698A
(en)
|
1997-09-10 |
1999-03-29 |
Ono Pharmaceutical Co. Ltd. |
Peroxisome proliferator-activated receptor controllers
|
|
GB2329334A
(en)
|
1997-09-18 |
1999-03-24 |
Reckitt & Colmann Prod Ltd |
Cholesterol-lowering agents
|
|
CA2214895C
(en)
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
|
WO1999015520A1
(en)
|
1997-09-19 |
1999-04-01 |
Ono Pharmaceutical Co., Ltd. |
Fused or nonfused benzene compounds
|
|
US6274603B1
(en)
|
1997-09-24 |
2001-08-14 |
Mcgill University |
Methods for increasing ApoE levels for the treatment of neurodegenerative disease
|
|
ES2180201T3
(es)
|
1997-10-07 |
2003-02-01 |
Boehringer Ingelheim Ca Ltd |
Derivados de azetidinona para el tratamiento de infecciones por hcmv.
|
|
IE970731A1
(en)
|
1997-10-07 |
2000-10-04 |
Fuisz Internat Ltd |
Product and method for the treatment of hyperlipidemia
|
|
US6147109A
(en)
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
|
CN1302206A
(zh)
|
1997-10-17 |
2001-07-04 |
阿温蒂斯药物制品公司 |
喹啉衍生物的治疗用途
|
|
US20030153541A1
(en)
*
|
1997-10-31 |
2003-08-14 |
Robert Dudley |
Novel anticholesterol compositions and method for using same
|
|
KR20010031501A
(ko)
|
1997-10-31 |
2001-04-16 |
추후제출 |
5-알파 환원효소 활성을 조절하는 방법 및 조성물
|
|
US6027747A
(en)
|
1997-11-11 |
2000-02-22 |
Terracol; Didier |
Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
|
|
AU1809499A
(en)
|
1997-12-10 |
1999-06-28 |
Awadhesh K. Mishra |
Self-emulsifying fenofibrate formulations
|
|
US5985936A
(en)
|
1997-12-18 |
1999-11-16 |
Forbes Medi-Tech, Inc. |
Method of preventing and delaying onset of Alzheimer's disease and composition therefor
|
|
US6008237A
(en)
|
1997-12-19 |
1999-12-28 |
Merck & Co., Inc. |
Arylthiazolidinedione derivatives
|
|
AU762124B2
(en)
|
1998-01-28 |
2003-06-19 |
Warner-Lambert Company |
Method for treating Alzheimer's disease
|
|
JP2002501909A
(ja)
|
1998-01-29 |
2002-01-22 |
ドクター・レディーズ・リサーチ・ファウンデーション |
新規なアルカン酸およびその医薬における使用、並びにその製造方法、およびそれを含有する薬学的組成物
|
|
US6200995B1
(en)
|
1998-01-29 |
2001-03-13 |
Tularik Inc. |
PPAR-γ modulators
|
|
US6133001A
(en)
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
|
KR100620337B1
(ko)
|
1998-03-10 |
2006-09-13 |
오노 야꾸힝 고교 가부시키가이샤 |
카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
|
|
US6235311B1
(en)
|
1998-03-18 |
2001-05-22 |
Bristol-Myers Squibb Company |
Pharmaceutical composition containing a combination of a statin and aspirin and method
|
|
US6080778A
(en)
|
1998-03-23 |
2000-06-27 |
Children's Medical Center Corporation |
Methods for decreasing beta amyloid protein
|
|
US6180625B1
(en)
|
1998-03-24 |
2001-01-30 |
Novo Nordisk A/S |
Heterocyclic compounds regulating clotting
|
|
DE69920888T2
(de)
|
1998-03-27 |
2006-02-02 |
Bristol-Myers Squibb Pharma Co. |
Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
|
|
WO1999008501A2
(en)
*
|
1998-04-23 |
1999-02-25 |
Dr. Reddy's Research Foundation |
New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
|
ID26128A
(id)
|
1998-04-29 |
2000-11-23 |
Ortho Mcneil Pharm Inc |
Senyawa-senyawa aminotetralin tersubstitusi-n sebagai ligan-ligan untuk reseptor neupeptida y y5 yang bermanfaat dalam pengobatan obesitas dan gangguan-gangguan lain
|
|
CN100357281C
(zh)
|
1998-05-27 |
2007-12-26 |
雷迪实验室有限公司 |
双环化合物、其制备方法和包含它们的药物组合物
|
|
US6262042B1
(en)
|
1998-05-29 |
2001-07-17 |
Research Triangle Institute |
17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
|
FR2779347A1
(fr)
|
1998-06-05 |
1999-12-03 |
Arlette Guerry |
Procede de micronisation de substances medicamenteuses
|
|
WO1999066930A1
(en)
|
1998-06-24 |
1999-12-29 |
Merck & Co., Inc. |
Compositions and methods for treating elevated blood cholesterol
|
|
JP2002518448A
(ja)
|
1998-06-24 |
2002-06-25 |
メルク エンド カムパニー インコーポレーテッド |
高血中コレステロールを治療する組成物および方法
|
|
US6099865A
(en)
|
1998-07-08 |
2000-08-08 |
Fmc Corporation |
Croscarmellose taste masking
|
|
FR2781222A1
(fr)
|
1998-07-17 |
2000-01-21 |
Lipha |
Composes cycliques utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procede de preparation
|
|
DE69911975T2
(de)
|
1998-07-31 |
2004-09-09 |
Novo Nordisk A/S |
In-vitro stimulation von beta zellen vermehrung
|
|
ATE315033T1
(de)
|
1998-08-07 |
2006-02-15 |
Chiron Corp |
Subtituierte isoxazole derivate als estrogen rezeptor modulatore
|
|
US6147090A
(en)
|
1998-09-17 |
2000-11-14 |
Pfizer Inc. |
4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
|
|
FR2783421B1
(fr)
|
1998-09-17 |
2000-11-24 |
Cll Pharma |
Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
|
|
OA11787A
(en)
|
1998-09-30 |
2005-07-26 |
Warner Lambert Co |
Method for preventing or delaying catheter-based revascularization.
|
|
US5919672A
(en)
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
|
WO2000023415A1
(en)
|
1998-10-21 |
2000-04-27 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
WO2000023416A1
(en)
|
1998-10-21 |
2000-04-27 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
EP1123292A1
(en)
|
1998-10-21 |
2001-08-16 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
JP2002527520A
(ja)
|
1998-10-21 |
2002-08-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規化合物、その製造及び使用
|
|
US6248781B1
(en)
|
1998-10-21 |
2001-06-19 |
Novo Nordisk A/S |
Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
|
|
EP1123279A1
(en)
|
1998-10-21 |
2001-08-16 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
CA2253769C
(en)
|
1998-11-10 |
2000-09-26 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising fenofibrate
|
|
US6472421B1
(en)
|
1998-11-13 |
2002-10-29 |
Nymox Corporation |
Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
|
|
AU1742200A
(en)
|
1998-11-25 |
2000-06-13 |
Eli Lilly And Company |
Prevention and treatment of amyloid-associated disorders
|
|
SA99191255B1
(ar)
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
|
CA2353981C
(en)
|
1998-12-07 |
2005-04-26 |
Schering Corporation |
Process for the synthesis of azetidinones
|
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
|
US6277584B1
(en)
|
1998-12-16 |
2001-08-21 |
Dade Behring Inc. |
Method for calibrating a chemical analyzer with improved accuracy at low signal levels
|
|
DE19858789A1
(de)
|
1998-12-18 |
2000-06-21 |
Bayer Ag |
Kombination von Cerivastatin und Fibraten
|
|
EP1140036A2
(en)
|
1998-12-18 |
2001-10-10 |
Abbott Laboratories |
Novel formulations comprising lipid-regulating agents
|
|
DE69908644T2
(de)
|
1998-12-23 |
2004-05-13 |
G.D. Searle Llc, Chicago |
Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
|
ATE226448T1
(de)
|
1998-12-23 |
2002-11-15 |
Searle Llc |
Kombinationen von ileumgallensäuretransports inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
|
|
KR20010102964A
(ko)
|
1998-12-23 |
2001-11-17 |
윌리암스 로저 에이 |
심장혈관 징후를 위한 회장 담즙산 수송 억제인자 및피브린산 유도체의 조합물
|
|
CA2356422C
(en)
|
1998-12-23 |
2008-09-16 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
|
PT1140184E
(pt)
|
1998-12-23 |
2003-10-31 |
Searle Llc |
Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
|
|
US6462091B1
(en)
|
1998-12-23 |
2002-10-08 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
|
|
CN1338945A
(zh)
|
1998-12-23 |
2002-03-06 |
G·D·瑟尔有限公司 |
适用于心血管疾病的回肠胆汁酸转运抑制剂和胆汁酸螯合剂组合
|
|
PL348503A1
(en)
|
1998-12-23 |
2002-05-20 |
Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
|
EA200100704A1
(ru)
*
|
1998-12-23 |
2002-02-28 |
Джи.Ди.Сирл Ллс |
Комбинация для применения по сердечно-сосудистым показаниям
|
|
AR022204A1
(es)
|
1999-01-08 |
2002-09-04 |
Norgine Bv |
Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
|
|
US6180138B1
(en)
|
1999-01-29 |
2001-01-30 |
Abbott Laboratories |
Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
|
|
GB0000710D0
(en)
|
1999-02-06 |
2000-03-08 |
Zeneca Ltd |
Drug combination
|
|
AU2690600A
(en)
|
1999-02-24 |
2000-09-14 |
Fuji Chemical Industries, Ltd. |
2-mercaptocarboxylic acid derivatives
|
|
EP1161236A1
(en)
|
1999-03-08 |
2001-12-12 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
|
|
EP1036563A1
(en)
|
1999-03-08 |
2000-09-20 |
MERCK & CO. INC. |
Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
|
|
ATE306263T1
(de)
|
1999-03-10 |
2005-10-15 |
Searle Llc |
Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere
|
|
KR20020010581A
(ko)
|
1999-03-11 |
2002-02-04 |
사단호진 산교 소죠켄큐쇼 |
핵수용체 ｐｐａｒ의 신규한 리간드
|
|
EP1175246A4
(en)
|
1999-03-19 |
2004-12-15 |
Brigham & Womens Hospital |
POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE OF TYPE III ENDOTHELIAL CELLS BY HMG-COA REDUCTASE INHIBITORS
|
|
MXPA01009839A
(es)
|
1999-03-31 |
2002-06-21 |
Abbott Lab |
Nuevas formulaciones que comprenden agentes reguladores de lipido.
|
|
HK1043936A1
(zh)
|
1999-03-31 |
2002-10-04 |
Abbott Laboratories |
含有脂调节剂的新的配方
|
|
AU3382699A
(en)
|
1999-04-05 |
2000-10-23 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of - (4-fluorophenyl) - 3(r)-(3(s) - hydroxy-3 (4-fluorophenyl) propyl))-4(s) (4-hydroxyphenyl)-2-azetidinone
|
|
US6593078B1
(en)
|
1999-04-16 |
2003-07-15 |
Schering Corporation |
Use of azetidinone compounds
|
|
EP1173408B1
(en)
|
1999-04-19 |
2005-07-20 |
Coelacanth Corporation |
Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
|
|
PL351312A1
(en)
|
1999-04-20 |
2003-04-07 |
Novo Nordisk As |
New compounds, their preparation and use
|
|
WO2000063196A1
(en)
|
1999-04-20 |
2000-10-26 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
AU3958100A
(en)
|
1999-04-20 |
2000-11-02 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
JP2002542237A
(ja)
|
1999-04-20 |
2002-12-10 |
ノボ ノルディスク アクティーゼルスカブ |
新規な化合物、それらの製造及び使用
|
|
CA2270306C
(en)
|
1999-04-27 |
2000-09-26 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising co-micronized fenofibrate
|
|
US6033656A
(en)
|
1999-05-04 |
2000-03-07 |
Sumitomo Chemical Company, Limited |
Method of preventing or alleviating mammalian obesity
|
|
WO2000069445A1
(en)
|
1999-05-13 |
2000-11-23 |
Geltex Pharmaceuticals, Inc. |
Combination therapy for treating hypercholesterolemia
|
|
EP1183011A4
(en)
|
1999-05-14 |
2005-01-19 |
Esperion Luv Dev Inc |
METHOD FOR THE TREATMENT OF ANGINA AND / OR SIMILAR ILLNESSES AND THE MEDICINAL PRODUCTS AND KITS THEREOF
|
|
JP2003500439A
(ja)
|
1999-05-28 |
2003-01-07 |
アボット・ラボラトリーズ |
脂質調節剤を含む新規調合物
|
|
US6465011B2
(en)
|
1999-05-29 |
2002-10-15 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
|
JP4618845B2
(ja)
|
1999-06-09 |
2011-01-26 |
杏林製薬株式会社 |
ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
|
|
US6372251B2
(en)
|
1999-06-11 |
2002-04-16 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
|
GB9913782D0
(en)
|
1999-06-14 |
1999-08-11 |
Smithkline Beecham Plc |
Novel compounds
|
|
US6380191B1
(en)
|
1999-06-18 |
2002-04-30 |
Merck & Co. Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
|
JP2003502369A
(ja)
|
1999-06-18 |
2003-01-21 |
メルク エンド カムパニー インコーポレーテッド |
アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
|
|
US6207699B1
(en)
|
1999-06-18 |
2001-03-27 |
Richard Brian Rothman |
Pharmaceutical combinations for treating obesity and food craving
|
|
GB9914977D0
(en)
|
1999-06-25 |
1999-08-25 |
Glaxo Group Ltd |
Chemical compounds
|
|
WO2001000579A1
(en)
|
1999-06-30 |
2001-01-04 |
Tularik Inc. |
COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
|
|
MXPA02001196A
(es)
|
1999-08-03 |
2003-02-12 |
Lilly Icos Llc |
Composiciones farmaceuticas de °-carbolina.
|
|
EP1078632A1
(en)
|
1999-08-16 |
2001-02-28 |
Sanofi-Synthelabo |
Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
|
|
GB9919413D0
(en)
|
1999-08-18 |
1999-10-20 |
Zeneca Ltd |
Chemical compounds
|
|
GB9919411D0
(en)
|
1999-08-18 |
1999-10-20 |
Zeneca Ltd |
Chemical compounds
|
|
ATE296815T1
(de)
|
1999-08-23 |
2005-06-15 |
Kyorin Seiyaku Kk |
Substituierte benzylthiazolidin-2,4-dion derivate
|
|
WO2001014350A1
(en)
|
1999-08-23 |
2001-03-01 |
Kyorin Pharmaceutical Co., Ltd. |
Substituted benzylthiazolidine-2,4-dione derivatives
|
|
DE60020381T2
(de)
|
1999-08-23 |
2006-01-26 |
Kyorin Pharmaceutical Co., Ltd. |
Substituierte benzylthiazolidin-2,4-dion-derivate
|
|
CA2382966A1
(en)
|
1999-08-27 |
2001-03-08 |
Eli Lilly And Company |
Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
|
|
AU782386C
(en)
|
1999-08-31 |
2006-08-10 |
Brigham And Women's Hospital |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
|
CA2384089A1
(en)
|
1999-09-08 |
2001-03-15 |
Genentech, Inc. |
Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
|
|
ES2215719T3
(es)
|
1999-09-08 |
2004-10-16 |
Glaxo Group Limited |
Antagonista ppar oxazol.
|
|
US6174665B1
(en)
|
1999-09-10 |
2001-01-16 |
Biex, Inc. |
Hormone replacement therapy monitoring
|
|
EP1219595B1
(en)
|
1999-09-17 |
2006-01-18 |
Kyorin Pharmaceutical Co., Ltd. |
O-anisamide derivatives
|
|
AU3885901A
(en)
|
1999-09-21 |
2001-04-24 |
Emory University |
Methods and compositions for treating platelet-related disorders
|
|
EP1214351A2
(en)
|
1999-09-22 |
2002-06-19 |
Genset |
Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
|
|
ATE288757T1
(de)
|
1999-09-24 |
2005-02-15 |
Kyorin Seiyaku Kk |
Ppar-alpha und ppar-gamma-hemmer
|
|
AU7717500A
(en)
|
1999-09-30 |
2001-04-30 |
Merck & Co., Inc. |
Anti-hypercholesterolemic drug combination
|
|
AU2833701A
(en)
|
1999-09-30 |
2001-05-10 |
Shell Internationale Research Maatschappij B.V. |
Adducts of glycidylesters of alpha, alpha-branched carboxylic acids and carboxylic acids and poly(ortho ester) as intermediate for their preparation
|
|
AU7995300A
(en)
|
1999-10-05 |
2001-05-10 |
Bethesda Pharmaceuticals, Inc. |
Dithiolane derivatives
|
|
EP1284728A4
(en)
|
1999-10-22 |
2004-05-19 |
Merck & Co Inc |
MEDICINES FOR TREATING ADDICTIC ADDICTION
|
|
AU780624B2
(en)
|
1999-11-04 |
2005-04-07 |
Andrx Corporation |
Method of treating amyloid beta precursor disorders
|
|
AU1304601A
(en)
|
1999-11-11 |
2001-06-06 |
Kyorin Pharmaceutical Co. Ltd. |
Solid preparations for oral use
|
|
EP1227828A1
(en)
|
1999-11-12 |
2002-08-07 |
Oncolytics Biotech, Inc. |
Viruses for the treatment of cellular proliferative disorders
|
|
CN1215059C
(zh)
|
1999-12-03 |
2005-08-17 |
京都药品工业株式会社 |
新的杂环化合物及其盐和它们的医药用途
|
|
ES2240209T3
(es)
|
1999-12-08 |
2005-10-16 |
Pharmacia Corporation |
Composiciones de eplerenona nanoparticulada.
|
|
AU2276801A
(en)
|
1999-12-20 |
2001-07-03 |
Schering Corporation |
Extended release oral dosage composition
|
|
US6248359B1
(en)
|
2000-01-05 |
2001-06-19 |
Laboratorios Phoenix U.S.A., Inc. |
Multi-tablet oxybutynin system for treating incontinence
|
|
US20010028895A1
(en)
|
2000-02-04 |
2001-10-11 |
Bisgaier Charles L. |
Methods of treating alzheimer's disease
|
|
CA2400021A1
(en)
|
2000-02-18 |
2001-08-23 |
Merck & Co., Inc. |
Aryloxyacetic acids for diabetes and lipid disorders
|
|
EE05442B1
(et)
|
2000-02-29 |
2011-08-15 |
Bristol-Myers Squibb Company |
Vikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
|
|
WO2001076632A1
(en)
|
2000-04-10 |
2001-10-18 |
Wald Nicholas J |
Formulation for the prevention of cardiovascular disease
|
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
|
US20020013334A1
(en)
|
2000-06-15 |
2002-01-31 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
|
US6191117B1
(en)
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
|
DE60128475T2
(de)
|
2000-07-25 |
2008-02-07 |
Merck & Co., Inc. |
N-substituierte indole mit anwendung in der behandlung von diabetes
|
|
US20020132855A1
(en)
*
|
2000-08-03 |
2002-09-19 |
Nelson Edward B. |
Use of acetaminophen to prevent and treat arteriosclerosis
|
|
DE10042447A1
(de)
*
|
2000-08-29 |
2002-03-28 |
Aventis Pharma Gmbh |
Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
|
|
AU9287401A
(en)
*
|
2000-09-27 |
2002-04-08 |
Merck & Co Inc |
Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
JP4351842B2
(ja)
|
2000-12-20 |
2009-10-28 |
シェーリング コーポレイション |
低コレステロール血症剤として有用な糖置換２−アゼチジノン
|
|
MXPA03005019A
(es)
*
|
2000-12-21 |
2003-09-25 |
Avantis Pharma Deutschland Gmb |
Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso.
|
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
|
MXPA03005155A
(es)
*
|
2000-12-21 |
2003-09-10 |
Aventis Pharma Gmbh |
1,2-difenilazetidinonas novedosas, procesos para su preparacion, farmacos que contienen compuestos y su uso para el tratamiento del metabolismo afectado de los lipidos.
|
|
MEP27808A
(en)
|
2001-01-26 |
2010-10-10 |
Schering Corp |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
TW200840563A
(en)
|
2001-01-26 |
2008-10-16 |
Schering Corp |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
|
|
WO2002058733A2
(en)
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
PT1355644E
(pt)
|
2001-01-26 |
2006-11-30 |
Schering Corp |
Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
|
|
NZ542090A
(en)
|
2001-01-26 |
2006-09-29 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
|
NZ545332A
(en)
|
2001-01-26 |
2007-09-28 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
|
|
JP2004521124A
(ja)
*
|
2001-02-09 |
2004-07-15 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類
|
|
DE10106787A1
(de)
|
2001-02-12 |
2002-08-22 |
Nanogate Gmbh |
Wasserfrei hydrolisierte Sol-Gel-Systeme
|
|
EP1372632A1
(en)
|
2001-02-15 |
2004-01-02 |
Pfizer Products Inc. |
Proliferative activator receptor (ppar) compounds
|
|
WO2002064549A1
(en)
|
2001-02-15 |
2002-08-22 |
Pfizer Products Inc. |
Ppar agonists
|
|
AU2002336267B2
(en)
*
|
2001-03-08 |
2006-10-05 |
Merck & Co., Inc. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
|
US7348334B2
(en)
*
|
2001-04-09 |
2008-03-25 |
Dr. Reddy's Laboratories Limited |
Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
|
|
WO2002081454A1
(en)
*
|
2001-04-09 |
2002-10-17 |
Dr. Reddy's Laboratories Ltd. |
Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
|
DE60216275T2
(de)
|
2001-05-25 |
2007-06-21 |
Schering Corp. |
Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
|
|
HRP20040171A2
(en)
|
2001-08-22 |
2004-10-31 |
Aventis Pharma Gmbh |
Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
|
|
EP1420826A2
(de)
|
2001-08-22 |
2004-05-26 |
Aventis Pharma Deutschland GmbH |
Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung
|
|
US20030119808A1
(en)
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
|
MXPA04002572A
(es)
|
2001-09-21 |
2004-05-31 |
Schering Corp |
Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
|
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
US7132415B2
(en)
|
2001-09-21 |
2006-11-07 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
|
|
WO2003039542A1
(en)
|
2001-10-17 |
2003-05-15 |
Merck & Co. Inc. |
Combination therapy for treating alzheimer's disease
|
|
WO2003074101A1
(en)
|
2002-02-28 |
2003-09-12 |
Eli Lilly And Company |
Method of treating atherosclerosis and hypercholesterolemia
|
|
AU2003225027A1
(en)
|
2002-04-16 |
2003-11-03 |
Merck And Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|